These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 33600756)
1. Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran - Authors' reply. Darvishian M; Sharafkhah M; Poustchi H; Malekzadeh R Lancet Infect Dis; 2021 May; 21(5):604-605. PubMed ID: 33600756 [No Abstract] [Full Text] [Related]
2. Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran. Nazemipour M; Shakiba M; Mansournia MA Lancet Infect Dis; 2021 May; 21(5):603-604. PubMed ID: 33600757 [No Abstract] [Full Text] [Related]
3. Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran. Ghafari M; Kadivar A; Katzourakis A Lancet Infect Dis; 2021 May; 21(5):602-603. PubMed ID: 33600759 [No Abstract] [Full Text] [Related]
4. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441 [TBL] [Abstract][Full Text] [Related]
5. Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study. Zamani M; Poustchi H; Mohammadi Z; Dalvand S; Sharafkhah M; Motevalian SA; Eslami S; Emami A; Somi MH; Yazdani-Charati J; Saki N; Karami M; Najafi F; Mohebbi I; Veisi N; Hormati A; Pourfarzi F; Ghadimi R; Ansari-Moghaddam A; Sharifi H; Roshandel G; Mansour-Ghanaei F; Joukar F; Shayanrad A; Eghtesad S; Niavarani A; Delavari A; Kaveh S; Feizesani A; Markarian M; Shafighian F; Sadjadi A; Darvishian M; Malekzadeh R BMC Public Health; 2022 May; 22(1):1031. PubMed ID: 35606743 [TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020. Shakiba M; Nazemipour M; Salari A; Mehrabian F; Nazari SSH; Rezvani SM; Ghasempour Z; Heidarzadeh A; Mansournia MA Emerg Infect Dis; 2021 Feb; 27(2):636-638. PubMed ID: 33349310 [TBL] [Abstract][Full Text] [Related]
7. High Seroprevalence of SARS-CoV-2 (COVID-19)-Specific Antibodies among Healthcare Workers: A Cross-Sectional Study in Guilan, Iran. Balou HA; Yaghubi Kalurazi T; Joukar F; Hassanipour S; Shenagari M; Khoshsorour M; Mansour-Ghanaei F J Environ Public Health; 2021; 2021():9081491. PubMed ID: 34691195 [TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 Seroprevalence Among Health Care Workers in Major Private and Public Hospitals With COVID-19 Patient's Referral in Tehran, Iran. Darvishian M; Sharafkhah M; Mohammadi Z; Sadeghniiat-Haghighi K; Abdollahi A; Jafary M; Talaschian M; Tabarsi P; Baghai P; Mardani M; Shayanrad A; Shafighian F; Markarian M; Roozafzai F; Zamani M; Alvand S; Hariri S; Sadeghi A; Poustchi H; Malekzadeh R Front Public Health; 2022; 10():832003. PubMed ID: 35400056 [TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Seroprevalence in People Referred to Private Medical Laboratories in Different Districts of Tehran, Iran from May 2020 to April 2021. Heydarifard Z; Zadheidar S; Yavarian J; Kalantari S; Nejati A; Mokhtari-Azad T; Shafiei-Jandaghi NZ Virol Sin; 2021 Oct; 36(5):1236-1240. PubMed ID: 34591252 [No Abstract] [Full Text] [Related]
10. Nationwide seroprevalence of antibodies to SARS-CoV-2 in asymptomatic population in South Korea: a cross-sectional study. Nah EH; Cho S; Park H; Hwang I; Cho HI BMJ Open; 2021 Apr; 11(4):e049837. PubMed ID: 33895722 [TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline. Bolotin S; Tran V; Osman S; Brown KA; Buchan SA; Joh E; Deeks SL; Allen VG J Infect Dis; 2021 Apr; 223(8):1334-1338. PubMed ID: 33400794 [TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Seroprevalence Following a Large-Scale Vaccination Campaign in Portugal: Results of the National Serological Survey, September - November 2021. Kislaya I; Gonçalves P; Ramalhete S; Barreto M; Torres AR; Gaio V; Gómez V; Manita C; Almeida Santos J; Soeiro S; De Sousa R; Melo A; Henriques C; Guiomar R; Rodrigues AP; Acta Med Port; 2023 Jan; 36(1):5-14. PubMed ID: 36288645 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2: big seroprevalence data from Pakistan-is herd immunity at hand? Haq M; Rehman A; Ahmad J; Zafar U; Ahmed S; Khan MA; Naveed A; Rajab H; Muhammad F; Naushad W; Aman M; Rehman HU; Ahmad S; Anwar S; Haq NU Infection; 2021 Oct; 49(5):983-988. PubMed ID: 34032997 [TBL] [Abstract][Full Text] [Related]
15. Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Javadinia SA; Ariamanesh M; Nabavifard M; Porouhan P; PeyroShabany B; Fazilat-Panah D; Hatami F; Ghasemi A; Lyman GH; Welsh JS; Ashkar Tizabi S; Dehghani M Cancer Invest; 2022 Feb; 40(2):115-123. PubMed ID: 34699294 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in the Mozambican Population: A Cross-Sectional Serologic Study in 3 Cities, July-August 2020. Arnaldo P; Mabunda N; Young PW; Tran T; Sitoe N; Chelene I; Nhanombe A; Ismael N; Júnior A; Cubula B; Inlamea OF; Gudo E; Jani IV Clin Infect Dis; 2022 Oct; 75(Suppl 2):S285-S293. PubMed ID: 35748663 [TBL] [Abstract][Full Text] [Related]
17. Prevalence of antibodies to SARS-CoV-2 in Irish hospital healthcare workers. Allen N; Riain UN; Conlon N; Ferenczi A; Carrion Martin AI; Domegan L; Walsh C; Doherty L; O'Farrelly C; Higgins E; Kerr C; McGrath J; ; Fleming C; Bergin C Epidemiol Infect; 2021 Apr; 149():e157. PubMed ID: 33902786 [TBL] [Abstract][Full Text] [Related]
18. Prevalence of Anti-SARS-CoV-2 Specific Antibodies in Health-Care Workers Compared to General Population during an Early Phase of the Pandemic, Tehran-Iran. Mortezagholi S; Rostamzadeh D; Alinejad M; Younesi V; Tabarsi P; Shabani M Iran J Immunol; 2021 Mar; 18(1):82-92. PubMed ID: 33787517 [TBL] [Abstract][Full Text] [Related]
19. Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021. Jones JM; Stone M; Sulaeman H; Fink RV; Dave H; Levy ME; Di Germanio C; Green V; Notari E; Saa P; Biggerstaff BJ; Strauss D; Kessler D; Vassallo R; Reik R; Rossmann S; Destree M; Nguyen KA; Sayers M; Lough C; Bougie DW; Ritter M; Latoni G; Weales B; Sime S; Gorlin J; Brown NE; Gould CV; Berney K; Benoit TJ; Miller MJ; Freeman D; Kartik D; Fry AM; Azziz-Baumgartner E; Hall AJ; MacNeil A; Gundlapalli AV; Basavaraju SV; Gerber SI; Patton ME; Custer B; Williamson P; Simmons G; Thornburg NJ; Kleinman S; Stramer SL; Opsomer J; Busch MP JAMA; 2021 Oct; 326(14):1400-1409. PubMed ID: 34473201 [TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 seroprevalence in the adult detainees of the Paris area in 2021: A multicenter cross-sectional study. Mellon G; Rouquette A; Fac C; Carton B; Cordonnier F; David E; Goutte B; Heulin F; Kanoui V; Levasseur L; Racle P; Silberman B; Nehri K; Dulioust A; Roque-Afonso AM J Infect; 2022 Aug; 85(2):e40-e43. PubMed ID: 35659551 [No Abstract] [Full Text] [Related] [Next] [New Search]